CA1339933C - Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux - Google Patents

Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux

Info

Publication number
CA1339933C
CA1339933C CA000582739A CA582739A CA1339933C CA 1339933 C CA1339933 C CA 1339933C CA 000582739 A CA000582739 A CA 000582739A CA 582739 A CA582739 A CA 582739A CA 1339933 C CA1339933 C CA 1339933C
Authority
CA
Canada
Prior art keywords
milk
hyperimmune
type
streptococcus pyogenes
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000582739A
Other languages
English (en)
Inventor
Lee R. Beck
Donald P. Kotler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stolle Milk Biologics Inc
Original Assignee
Stolle Research and Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research and Development Corp filed Critical Stolle Research and Development Corp
Priority to CA000582739A priority Critical patent/CA1339933C/fr
Application granted granted Critical
Publication of CA1339933C publication Critical patent/CA1339933C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA000582739A 1988-11-10 1988-11-10 Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux Expired - Fee Related CA1339933C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000582739A CA1339933C (fr) 1988-11-10 1988-11-10 Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000582739A CA1339933C (fr) 1988-11-10 1988-11-10 Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux

Publications (1)

Publication Number Publication Date
CA1339933C true CA1339933C (fr) 1998-06-30

Family

ID=4139079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000582739A Expired - Fee Related CA1339933C (fr) 1988-11-10 1988-11-10 Utilisation de produit laitier hyperimmun pour traiter les troubles gastro-intestinaux

Country Status (1)

Country Link
CA (1) CA1339933C (fr)

Similar Documents

Publication Publication Date Title
US5106618A (en) Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
US5080895A (en) Specific antibody-containing substance from eggs and method of production and use thereof
Foy et al. Myeoplasma pneumoniae infections in patients with immunodeficiency syndromes: report of four cases
US6329002B1 (en) Food for inhibiting infection and treating gastritis, gastric and duodenal ulcers
CA2260007C (fr) Procede pour prevenir, contrer, ou reduire les lesions gastro-intestinales
JP2002501526A (ja) 乳汁における免疫グロブリンａの生成方法
US6056978A (en) Use of hyperimmune milk to prevent suppression of T-lymphocyte production
JPH0657663B2 (ja) 多機能特異的抗体の製造方法
US20020009429A1 (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
AU621604B2 (en) Antihypertensive hyperimmune milk, production, composition, and use
EP0484148A1 (fr) Procédé de préparation d'un médicament pour à la fois, le traitement et la prévention d'ulcères peptiques gastriques et de la gastrite, et des médicaments ainsi formulés
JPH02160726A (ja) ワクチン
JPH08504167A (ja) スタフィロコーカス感染の予防及び処理のための指図されたヒト免疫グロブリン
CA1337265C (fr) Anticorps administres par voie orale pour le traitement de patients immunodeprimes et composition utilisee a cet effet
AU680617B2 (en) The use of hyperimmune milk to increase longevity
CA2233935A1 (fr) Procede d'isolement d'immunoglobuline a partir de petit lait
WO1999002188A1 (fr) Anticorps de jaune d'oeuf de poule, diriges contre les antigenes de clostridium difficile et leur utilisation dans le traitement de la colite pseudomembraneuse
Xu et al. Bovine immune colostrum against 17 strains of diarrhea bacteria and in vitro and in vivo effects of its specific IgG
US10478493B2 (en) Method of treating protozoal gastrointestinal disorders in immunocompromised patients
AU696237B1 (en) Prevention and treatment of enterohemorrhagic E.Coli infection
WO1993025232A9 (fr) Utilisation de lait hyperimmun pour augmenter la longevite
RU2062109C1 (ru) Способ получения иммунного препарата
IE76730B1 (en) Method and product for the treatment of gastric disease
WO1998055143A1 (fr) Formulation orale a teneur en lipides reduite contenant une proteine therapeutique derivee du jaune d'oeuf
JPH0372432A (ja) ロタウイルス感染症治療剤の製法

Legal Events

Date Code Title Description
MKLA Lapsed